Frank Wu

4.8k total citations · 1 hit paper
39 papers, 2.0k citations indexed

About

Frank Wu is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Frank Wu has authored 39 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Molecular Biology, 13 papers in Oncology and 11 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Frank Wu's work include Microtubule and mitosis dynamics (6 papers), Melanoma and MAPK Pathways (5 papers) and Cholangiocarcinoma and Gallbladder Cancer Studies (5 papers). Frank Wu is often cited by papers focused on Microtubule and mitosis dynamics (6 papers), Melanoma and MAPK Pathways (5 papers) and Cholangiocarcinoma and Gallbladder Cancer Studies (5 papers). Frank Wu collaborates with scholars based in United States, China and France. Frank Wu's co-authors include Paul Nathan, Mohammed Milhem, Piotr Rutkowski, James Larkin, Lev Demidov, Jessica C. Hassel, Reinhard Dummer, Jochen Utikal, Laurie Sherman and Dirk Schadendorf and has published in prestigious journals such as Circulation, Journal of Clinical Oncology and Blood.

In The Last Decade

Frank Wu

34 papers receiving 1.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group

2012 1.1k citations Frank Wu et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Frank Wu United States	15	1.3k	998	286	190	179	39	2.0k
Luna Musib United States	24	1.4k 1.1×	952 1.0×	483 1.7×	104 0.5×	405 2.3×	77	2.6k
Maria Cristina Sini Italy	22	1.0k 0.8×	710 0.7×	188 0.7×	205 1.1×	126 0.7×	59	1.5k
Emma Dean United Kingdom	29	1.8k 1.3×	1.4k 1.4×	390 1.4×	256 1.3×	222 1.2×	132	2.7k
Milena Casula Italy	23	864 0.7×	733 0.7×	328 1.1×	275 1.4×	126 0.7×	52	1.5k
Ilsung Chang United States	16	2.1k 1.6×	1.6k 1.6×	228 0.8×	281 1.5×	285 1.6×	34	2.7k
Victoria L. Chiou United States	9	617 0.5×	875 0.9×	375 1.3×	256 1.3×	182 1.0×	24	1.6k
Meilan Liu United States	18	995 0.7×	575 0.6×	292 1.0×	195 1.0×	98 0.5×	46	1.6k
Lorelei J. Hanson United States	15	1.1k 0.8×	971 1.0×	411 1.4×	79 0.4×	224 1.3×	20	1.8k
Osamu Kitahara Japan	14	1.3k 1.0×	498 0.5×	173 0.6×	122 0.6×	213 1.2×	18	2.0k
Efisio Puxeddu Italy	31	1.3k 1.0×	905 0.9×	344 1.2×	205 1.1×	284 1.6×	77	3.2k

Countries citing papers authored by Frank Wu

Since Specialization

Citations

This map shows the geographic impact of Frank Wu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Frank Wu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Frank Wu more than expected).

Fields of papers citing papers by Frank Wu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Frank Wu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Frank Wu. The network helps show where Frank Wu may publish in the future.

Co-authorship network of co-authors of Frank Wu

This figure shows the co-authorship network connecting the top 25 collaborators of Frank Wu. A scholar is included among the top collaborators of Frank Wu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Frank Wu. Frank Wu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Tang, Chenchen, Rui Zhong, Yuanhua Lu, et al.. (2025). Multiple Kinase Small Molecule Inhibitor Tinengotinib (TT‐00420) Alone or With Chemotherapy Inhibit the Growth of SCLC. Cancer Science. 116(4). 951–965. 1 indexed citations

Xu, Han, Xu Wang, Frank Wu, et al.. (2025). Emodin-induced ERα degradation via SYVN1 alleviates vascular calcification by preventing HIF-1α deacetylation in chronic kidney disease. Phytomedicine. 145. 156915–156915. 3 indexed citations

Fountzilas, Christos, Chih‐Yi Liao, Daneng Li, et al.. (2025). Tinengotinib in patients with advanced, metastatic cholangiocarcinoma: Overall survival results and biomarker correlative analysis from a phase 2 clinical trial.. Journal of Clinical Oncology. 43(4_suppl). 608–608.

Xue, Allen, Frank Wu, Tracie Barber, et al.. (2025). Determining a method for description and evaluation of heterogeneity of perfusion in the third-trimester placenta. Placenta. 174. 109–116.

Fountzilas, Christos, Chih‐Yi Liao, Daneng Li, et al.. (2025). Tinengotinib for adults with advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 trial. The Lancet. Gastroenterology & hepatology. 11(2). 137–149.

Zhang, Panpan, Jifang Gong, Zuoxing Niu, et al.. (2024). Tinengotinib (TT-00420) in combination with atezolizumab in Chinese patients (pts) with biliary tract carcinoma (BTC): Preliminary efficacy and safety results from a phase Ib/II study.. Journal of Clinical Oncology. 42(3_suppl). 473–473. 1 indexed citations

Javle, Milind, Lionel Aurelien Kankeu Fonkoua, Amit Mahipal, et al.. (2023). 95MO Tinengotinib in patients with advanced, fibroblast growth factor receptor (FGFR) inhibitor refractory/relapsed cholangiocarcinoma. Annals of Oncology. 34. S215–S216. 4 indexed citations

Li, Lin, Yixiang Wang, Qi Yu, et al.. (2023). In vitro and in vivo pharmacokinetics, disposition, and drug-drug interaction potential of tinengotinib (TT-00420), a promising investigational drug for treatment of cholangiocarcinoma and other solid tumors. European Journal of Pharmaceutical Sciences. 192. 106658–106658. 2 indexed citations

Yu, Qi, et al.. (2022). Tinengotinib (TT-00420), a Novel Spectrum-Selective Small-Molecule Kinase Inhibitor, Is Highly Active Against Triple-Negative Breast Cancer. Molecular Cancer Therapeutics. 22(2). 205–214. 17 indexed citations

10.

Lin, Ming-Huei, et al.. (2019). Dual trigger with gonadotropin releasing hormone agonist and human chorionic gonadotropin significantly improves live birth rate for women with diminished ovarian reserve. Reproductive Biology and Endocrinology. 17(1). 7–7. 41 indexed citations

11.

Liu, Dongyang, Yang Liu, Huimin Zhou, et al.. (2016). Quantitative prediction of human pharmacokinetics and pharmacodynamics of imigliptin, a novel DPP-4 inhibitor, using allometric scaling, IVIVE and PK/PD modeling methods. European Journal of Pharmaceutical Sciences. 89. 73–82. 14 indexed citations

12.

Liu, Dongyang, Hongzhong Liu, Lin Song, et al.. (2015). Simultaneous determination of imigliptin and its three metabolites in human plasma and urine by liquid chromatography coupled to tandem mass spectrometry. Journal of Chromatography B. 1002. 300–312. 2 indexed citations

13.

Blumenschein, George R., Egbert F. Smit, David Planchard, et al.. (2015). A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC). Annals of Oncology. 26(5). 894–901. 248 indexed citations

14.

Wu, Frank, Yuh‐Ming Hwu, Robert Kuo‐Kuang Lee, et al.. (2011). First trimester ultrasound estimation of gestational age in pregnancies conceived after in vitro fertilization. European Journal of Obstetrics & Gynecology and Reproductive Biology. 160(2). 151–155. 14 indexed citations

15.

Hwu, Yuh‐Ming, Frank Wu, Sheng‐Hsiang Li, et al.. (2011). The impact of endometrioma and laparoscopic cystectomy on serum anti-Müllerian hormone levels. Reproductive Biology and Endocrinology. 9(1). 80–80. 96 indexed citations

16.

Wu, Frank, Frank Büttner, Eugene R. Hickey, et al.. (2010). Substituted 2H-isoquinolin-1-one as potent Rho-Kinase inhibitors. Part 1: Hit-to-lead account. Bioorganic & Medicinal Chemistry Letters. 20(11). 3235–3239. 15 indexed citations

17.

Ginn, John D., Todd Bosanac, Charles L. Cywin, et al.. (2010). Substituted 2H-isoquinolin-1-ones as potent Rho-kinase inhibitors: Part 2, optimization for blood pressure reduction in spontaneously hypertensive rats. Bioorganic & Medicinal Chemistry Letters. 20(17). 5153–5156. 20 indexed citations

18.

Shao, Liming, Michael C. Hewitt, Thomas P. Jerussi, et al.. (2008). In vitro and in vivo evaluation of O-alkyl derivatives of tramadol. Bioorganic & Medicinal Chemistry Letters. 18(5). 1674–1680. 8 indexed citations

19.

Qian, Xiaozhong, William J. LaRochelle, Gulshan Ara, et al.. (2006). Activity of PXD101, a histone deacetylase inhibitor, in preclinical ovarian cancer studies. Molecular Cancer Therapeutics. 5(8). 2086–2095. 117 indexed citations

20.

Ort, Tatiana, Anibal A. Arjona, John R. MacDougall, et al.. (2005). Recombinant Human FIZZ3/Resistin Stimulates Lipolysis in Cultured Human Adipocytes, Mouse Adipose Explants, and Normal Mice. Endocrinology. 146(5). 2200–2209. 63 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact